On December 22, 2025, the FDA approved oral Wegovy (semaglutide 25mg tablet) the first and only oral GLP-1 medication for chronic weight management
Personalized Treatment: We tailor our semaglutide therapy to meet your specific needs, providing personalized treatment plans for each patient
In comparison, those who took a placebo lost an average of 2.6% of their starting body weight
In the case of GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), microdosing involves using a fraction of the typical dose to achieve benefits with potentially fewer side effects
How to get started with semaglutide injections
Taking care of a semaglutide vial is all about proper storage, careful handling, and being aware of the expiration dates